Oncology portfolio growth trends
During AstraZeneca’s (AZN) fourth-quarter earnings investor presentation, the company highlighted the potential of its oncology drug, Tagrisso, to become the highest-earning drug in its portfolio in 2019. In 2018, the drug was the highest-earning oncology drug and AstraZeneca’s second-highest-earning asset. Driven by the robust uptake of lung cancer drugs Tagrisso and Imfinzi, the company managed to report revenue of ~$6.0 billion from the sale of its oncology drugs in 2018, a YoY (year-over-year) rise of 49% and a sequential rise of 64%.
AstraZeneca reported a ~$2.0 billion YoY increase in oncology product sales in 2018, of which $1.9 billion came from the sale of its recently launched drugs. Additionally, according to the company’s fourth-quarter earnings conference call, AstraZeneca’s legacy oncology drug, Faslodex, managed to cross the $1.0 billion revenue milestone in 2018. This development was mainly attributable to the label expansion of Faslodex with CDK4/6 (cyclin-dependent kinase 4/6) inhibitors in metastatic hormone-receptor-positive breast cancer indications.
According to AstraZeneca’s fourth-quarter earnings press release, in 2018, Tagrisso reported revenue of $1.86 billion, a YoY rise of 95% on a reported basis and 93% on a constant exchange rate basis. This performance was driven mainly by the drug’s continued uptake in second-line EGFR T790M-mutated NSCLC indications and in the ongoing launch of the drug in first-line EGFR-mutated NSCL indications.
According to the company’s investor presentation, Tagrisso has emerged as the standard of care in the US market in first-line EGFR-mutated NSCLC indications, while the drug continues to be launched in these indications in Europe and the rest of the world.
According to AstraZeneca’s fourth-quarter earnings press release, in 2018, Imfinzi reported revenue of $633 million driven mainly by the ongoing launch of the drug in unresectable stage III NSCLC (non-small cell lung cancer) indications across multiple markets in the world.
According to the company’s investor presentation, Imfinzi is emerging as a new standard of care in unresectable stage III NSCLC indications in the US market. The drug is expected to report peak sales in excess of $1.0 billion in the US market. Most of Imfinzi’s 2018 revenue comes from the US market, although the drug has secured regulatory approvals in ~40 markets across the world.
According to AstraZeneca’s fourth-quarter earnings press release, in 2018, Lyparza reported revenue of $647 million driven mainly by its increased use in ovarian cancer and breast cancer indications.